Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ziqian Geng

Showing results (1-10 of 17) with videos related to

Pageof 2
Sort By:
Contemporary Clinical Trials|March 29, 2026
Accelerating medicines to patients: A Bayesian quantitative evidence-based decision-making framework with interim monitoringYihua Gu, Ziqian Geng, Tianyu Zhan, et al.
Statistical Methods in Medical Research|January 18, 2021
An automation-based adaptive seamless design for dose selection and confirmation with improved power and efficiencyLu Cui, Tianyu Zhan, Lanju Zhang, et al.
Statistics in Medicine|June 10, 2021
A practical response adaptive block randomization (RABR) design with analytic type I error protectionTianyu Zhan, Lu Cui, Ziqian Geng, et al.
Wounds : a Compendium of Clinical Research and Practice|November 23, 2017
Infection-free Clinical Response Among Patients With Hidradenitis Suppurativa Who Were Treated With Adalimumab: Results from Two Phase 3 StudiesEvangelos J Giamarellos-Bourboulis, Jeffrey Sobell, Caitriona Ryan, et al.
Acta Dermato-Venereologica|August 8, 2018
Achieving Hidradenitis Suppurativa Response Score is Associated with Significant Improvement in Clinical and Patient-reported Outcomes: Post Hoc Analysis of Pooled Data From PIONEER I and IIAlexandra B Kimball, Thrasivoulos Tzellos, Brian M Calimlim, et al.
The Journal of Biological Chemistry|May 28, 2026
Lactate-fueled H3K18 lactylation sustains ΔNp63α-dependent self-renewal in limbal epithelial stem cellsLongfei Li, Lin Zhu, Liyuan Wang, et al.
Journal of Biopharmaceutical Statistics|October 11, 2021
Deep historical borrowing framework to prospectively and simultaneously synthesize control information in confirmatory clinical trials with multiple endpointsTianyu Zhan, Yiwang Zhou, Ziqian Geng, et al.
The Journal of Dermatological Treatment|May 5, 2021
Efficacy, safety, usability, and acceptability of risankizumab 150 mg formulation administered by prefilled syringe or by an autoinjector for moderate to severe plaque psoriasisAndrew Blauvelt, Kenneth B Gordon, Patricia Lee, et al.
Dermatology and Therapy|March 9, 2023
Efficacy and Safety of Risankizumab for the Treatment of Hidradenitis Suppurativa: A Phase 2, Randomized, Placebo-Controlled TrialAlexa B Kimball, Errol P Prens, Thierry Passeron, et al.
JAMA Dermatology|October 14, 2020
Effect of Risankizumab on Patient-Reported Outcomes in Moderate to Severe Psoriasis: The UltIMMa-1 and UltIMMa-2 Randomized Clinical TrialsMatthias Augustin, Jo Lambert, Carla Zema, et al.
Pageof 2

Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
Contemporary Clinical Trials|March 29, 2026
Accelerating medicines to patients: A Bayesian quantitative evidence-based decision-making framework with interim monitoringYihua Gu, Ziqian Geng, Tianyu Zhan, et al.
Statistical Methods in Medical Research|January 18, 2021
An automation-based adaptive seamless design for dose selection and confirmation with improved power and efficiencyLu Cui, Tianyu Zhan, Lanju Zhang, et al.
Statistics in Medicine|June 10, 2021
A practical response adaptive block randomization (RABR) design with analytic type I error protectionTianyu Zhan, Lu Cui, Ziqian Geng, et al.
Wounds : a Compendium of Clinical Research and Practice|November 23, 2017
Infection-free Clinical Response Among Patients With Hidradenitis Suppurativa Who Were Treated With Adalimumab: Results from Two Phase 3 StudiesEvangelos J Giamarellos-Bourboulis, Jeffrey Sobell, Caitriona Ryan, et al.
Acta Dermato-Venereologica|August 8, 2018
Achieving Hidradenitis Suppurativa Response Score is Associated with Significant Improvement in Clinical and Patient-reported Outcomes: Post Hoc Analysis of Pooled Data From PIONEER I and IIAlexandra B Kimball, Thrasivoulos Tzellos, Brian M Calimlim, et al.
The Journal of Biological Chemistry|May 28, 2026
Lactate-fueled H3K18 lactylation sustains ΔNp63α-dependent self-renewal in limbal epithelial stem cellsLongfei Li, Lin Zhu, Liyuan Wang, et al.
Journal of Biopharmaceutical Statistics|October 11, 2021
Deep historical borrowing framework to prospectively and simultaneously synthesize control information in confirmatory clinical trials with multiple endpointsTianyu Zhan, Yiwang Zhou, Ziqian Geng, et al.
The Journal of Dermatological Treatment|May 5, 2021
Efficacy, safety, usability, and acceptability of risankizumab 150 mg formulation administered by prefilled syringe or by an autoinjector for moderate to severe plaque psoriasisAndrew Blauvelt, Kenneth B Gordon, Patricia Lee, et al.
Dermatology and Therapy|March 9, 2023
Efficacy and Safety of Risankizumab for the Treatment of Hidradenitis Suppurativa: A Phase 2, Randomized, Placebo-Controlled TrialAlexa B Kimball, Errol P Prens, Thierry Passeron, et al.
JAMA Dermatology|October 14, 2020
Effect of Risankizumab on Patient-Reported Outcomes in Moderate to Severe Psoriasis: The UltIMMa-1 and UltIMMa-2 Randomized Clinical TrialsMatthias Augustin, Jo Lambert, Carla Zema, et al.
Pageof 2